Beltran Pedro 4

4 · BridgeBio Oncology Therapeutics, Inc. · Filed Mar 12, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

BridgeBio Oncology (BBOT) CSO Pedro Beltran Receives 256,670-Share Award

What Happened

Pedro Beltran, Chief Scientific Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a total of 256,670 equity awards on 2026-03-10. The awards consist of 46,670 RSUs and 210,000 derivative awards (options or other equity-based units). All awards were granted at $0 per share (no cash paid). These are grants/awards (not open-market purchases or sales) and will vest over time per the schedules below.

Key Details

Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (timely filing).
Grants: 46,670 RSUs (F1) and 210,000 derivative awards (F2); total = 256,670 shares/units; grant price reported as $0.00.
Vesting:
- RSUs (F1): Vest in 16 equal quarterly installments over four years starting Jan 1, 2026; settled in shares upon vesting.
- Derivative award (F2): Vests 1/48th monthly beginning Jan 1, 2026 (monthly installments over four years).
Shares owned after transaction: Not disclosed in the Form 4.
Filing status: Not marked late; appears filed within the required two-business-day window.
Nature of transaction code: "A" = Award/Grant (routine equity compensation, not a sale or purchase).

Context

RSUs and the derivative award will convert to or allow acquisition of common shares only as they vest; there was no immediate sale or cashless exercise reported. Such grants are standard executive compensation and do not by themselves indicate an immediate bullish or bearish signal.

Form 4

Period: 2026-03-10

Chief Scientific Officer

Transactions

Award
Common Stock
[F1]
2026-03-10+46,670→ 46,670 total
Award
Stock Option (Right to Buy)
[F2]
2026-03-10+210,000→ 210,000 total
Exercise: $10.19Exp: 2036-03-09→ Common Stock (210,000 underlying)

Footnotes (2)

[F1]Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.
[F2]1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Signature

/s/ Uneek Mehra, Attorney-in-Fact|2026-03-12

1 file